Answers are grounded in this paper and cite their sources.
Therapeutic equivalence studies still present problems to regulatory reviewers from many perspectives. This paper is intended to discuss some of these concerns from the statistical viewpoint. There are, however, also some newer approaches which may be particularly useful for the investigation of therapeutic equivalence.
No takes yet. Share an insight, caveat, or question.
Joachim Röhmel (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: